Moderna (MRNA) is a publicly traded Healthcare sector company. As of May 20, 2026, MRNA trades at $48.28 with a market cap of $19.09B and a P/E ratio of -5.92. MRNA moved +5.33% today. Year to date, MRNA is +48.15%; over the trailing twelve months it is +73.25%. Its 52-week range spans $22.28 to $67.96. Analyst consensus is neutral with an average price target of $44.73. Rallies surfaces MRNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded MRNA stock?
Recent politician trading activity in MRNA includes disclosures from Ro Khanna, Rob Bresnahan, Julie Johnson, and Ro Khanna. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
MRNA Key Metrics
Key financial metrics for MRNA
Metric
Value
Price
$48.28
Market Cap
$19.09B
P/E Ratio
-5.92
EPS
$-8.15
Dividend Yield
0.00%
52-Week High
$67.96
52-Week Low
$22.28
Volume
3.87M
Avg Volume
0
Revenue (TTM)
$2.23B
Net Income
$-3.19B
Gross Margin
22.11%
Congressional Trades in MRNA
Ro Khanna purchase MRNA on Jul 25, 2025 (amount: $15.00K).
Rob Bresnahan purchase MRNA on Feb 25, 2025 (amount: $15.00K).
Julie Johnson sale MRNA on Jan 15, 2025 (amount: $15.00K) for Joint.
Ro Khanna sale MRNA on Sep 9, 2024 (amount: $15.00K).
Recent politician trading activity in MRNA includes disclosures from Ro Khanna, Rob Bresnahan, Julie Johnson, and Ro Khanna. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in MRNA?
Yes. Rallies tracks politician and congressional stock disclosures for MRNA, including reported purchases, sales, dates, owners, and trade amounts when available.
Is MRNA research on Rallies investment advice?
No. Rallies provides research, data, and educational context for MRNA. It does not provide personalized investment advice.
